BRUKER CORPORATION

(BRKR)
  Report
Real-time Estimate Cboe BZX  -  05/23 10:41:24 am EDT
60.28 USD   +0.09%
05/16Bruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to Shareholders as of June 1
MT
05/16Bruker Announces Quarterly Dividend
BU
05/16Bruker Corporation Announces Quarterly Cash Dividend, Payable on June 17, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bruker : Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry

12/07/2021 | 12:22pm EDT
Canopy Biosciences Launches the First of a Series of Targeted Assay Kits for ChipCytometry
Ready-to-Use Reagents to Advance Spatial Biology Research
Fluorescent image of human lung cancer FFPE sample with 13 protein biomarkers illuminated using the Spatial Immune Profiling Kit for ChipCytometry.

ST. LOUIS, Missouri - December 7, 2021 -Canopy Biosciences, a Bruker Company, today announced the launch of a first in a series of assay kits for ChipCytometryTM, a quantitative, high dynamic range (HDR) and high-resolution multiplexing technology for spatial proteomics. The Canopy assay kits are validated and optimized for use with the Canopy ZellScannerONETM instrument to quantitatively image dozens of targeted protein biomarkers simultaneously on a single tissue section at single-cell spatial resolution. ChipCytometry assay kits that are based on Canopy's extensive experience in their antibody biomarker panels for services will provide researchers with reliable, ready-to-use reagents that have been extensively validated in a variety of tissue types. The release of these assay kits will streamline the user experience with ChipCytometry for a shorter pathway to meaningful biological advances. This first Spatial Immune Profiling Kit is a comprehensive kit for highly multiplexed, quantitative spatial phenotyping of key immune cell populations in human formalin-fixed paraffin-embedded (FFPE) tissues.

"ChipCytometry assays enable us to investigate tissue samples and deeply phenotype cells. The time we spend in our lab optimizing assay conditions can be a challenge," said Lixin Zhang, M.D., Ph.D., Research Scientist at University of Pittsburgh Magee-Womens Research Institute. "Using pre-validated assay kits saves us precious time that we can spend on other lab activities. The kit will allow us to reliably test more samples in a shorter time frame."

Edward Weinstein, Ph.D., President at Canopy Biosciences, added: "These assay kits for ChipCytometry provide ready-to-use tools for highly quantitative, high-resolution and multiplexed proteomics studies for immuno-oncology, neuroscience and infectious disease research. Our scientists have extensive experience optimizing combinations of validated antibodies to create the highest quality data. The ChipCytometry assay kits will streamline researchers' ability to spatially profile the tumor microenvironment, by eliminating time spent on validation."

About ChipCytometry

ChipCytometrycombines high-resolution, high dynamic range imaging with advanced image analysis software to enable quantitative measurements of high-plex protein biomarker assays. The ZellScannerONE instrument is a fully integrated, automated imaging system that produces high-resolution, high-dynamic-range (HDR) images that are analyzed by powerful AI-driven software to quantify protein targets with true single-cell resolution. Using sequential staining and photobleaching on ZellSafeTM microfluidic chips, a virtually unlimited number of biomarkers can be visualized and quantified.For more information about Canopy Biosciences' ChipCytometry platform and the Spatial Immune Profiling Kit, please visit www.canopybiosciences.com.

About Canopy Biosciences, a Bruker Company

Canopy Biosciences was formed in 2016 and rapidly built a comprehensive portfolio of products and services for spatial biology, multi-omics, and bioprocessing. Canopy offers its ChipCytometry technology for precise spatial multiplexing in cells and tissue samples, along with other technologies of ultrasensitive DNA sequencing (RareSeq), RNA-Seq, and gene expression analysis for services. Canopy Biosciences is headquartered in St. Louis, Missouri, with additional CRO sites in California and Germany to serve researchers at universities, research institutions, and biotechnology and pharmaceutical companies worldwide. Canopy was acquired by Bruker Corporation (Nasdaq: BRKR) in 2020. Additional information is available at www.canopybiosciences.com.

Media Contact:
Kevin Gamber
Vice President, Marketing
Canopy Biosciences, A Bruker Company
T: +1 (314) 662-9987
E: kevin.gamber@bruker.com

Disclaimer

Bruker Corporation published this content on 07 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2021 17:21:03 UTC.


© Publicnow 2021
All news about BRUKER CORPORATION
05/16Bruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to ..
MT
05/16Bruker Announces Quarterly Dividend
BU
05/16Bruker Corporation Announces Quarterly Cash Dividend, Payable on June 17, 2022
CI
05/10Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions ..
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
CI
05/06BRUKER CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
05/05SVB Leerink Adjusts Bruker's Price Target to $87 from $85, Keeps Outperform Rating
MT
05/05Bruker Corporation acquired unknown minority stake in Tofwerk AG for CHF 18 million.
CI
05/04TRANSCRIPT : Bruker Corporation, Q1 2022 Earnings Call, May 04, 2022
CI
More news
Analyst Recommendations on BRUKER CORPORATION
More recommendations
Financials (USD)
Sales 2022 2 568 M - -
Net income 2022 300 M - -
Net Debt 2022 157 M - -
P/E ratio 2022 29,9x
Yield 2022 0,31%
Capitalization 8 988 M 8 988 M -
EV / Sales 2022 3,56x
EV / Sales 2023 3,30x
Nbr of Employees 7 765
Free-Float 57,8%
Chart BRUKER CORPORATION
Duration : Period :
Bruker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRUKER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 60,22 $
Average target price 75,63 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Frank H. Laukien Chairman, President & Chief Executive Officer
Gerald N. Herman Chief Financial Officer & Executive Vice President
William Alderman Linton Lead Independent Director
Richard A. Packer Independent Director
Hermann Fritz Requardt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BRUKER CORPORATION-28.23%8 988
THERMO FISHER SCIENTIFIC-16.80%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644